Biology subjects

Lopes, K. d. P.

Publications and source records attributed to Lopes, K. d. P..

6 recordsLinked to original sources

bioRxiv2025

Characterizing Post-Mortem Brain Molecular Taxonomy of Cognitive Resilience and Translating it to Living Humans

Here, we define cognitive resilience as slower or faster cognitive decline after we regress out the effects of common brain neuropathologies. Its understanding could provide important insights into the biology underlying cognitive health, enabling the development of more effective strategies to prevent cognitive decline and dementia. However, this requires the development of a practical method to quantify resilience and measure it in living individuals, as well as identifying heterogenous pathways associated with resilience in different individuals. Here, we approach this problem by using a data-driven framework to quantify and characterize molecular signatures underlying cognitive resilience. Using multimodal contrastive trajectory inference (mcTI) on bulk RNA sequencing and tandem mass tag (TMT) proteomic data from 898 post- mortem brain samples from the Religious Orders Study and the Rush Memory and Aging Project (ROSMAP), we derived individual-level molecular pseudotime values reflecting the molecular path from high to low resilience across individuals. Additionally, we identified two distinct molecular subtypes of resilience, each characterized by unique transcriptomic and proteomic signatures, and differing associations with several phenotypes. To translate our brain-derived pseudotime and subtypes to living individuals, we developed prediction models with paired genetics, ante-mortem blood omics, clinical, psychosocial, imaging and device data from the same individuals, demonstrating the potential to predict brain molecular resilience profiles in living persons. Our findings establish a framework for quantifying resilience based on multi- level molecular signatures, identify molecularly distinct resilience subtypes, and demonstrate the feasibility of translating brain-derived molecular profiles to living individuals--laying the groundwork for the development of targeted resilience-promoting interventions in cognitive aging.

neuroscience↗

bioRxiv2025

Brain Multi-Omic Subtypes of Neuroticism Reveal Molecular Signatures linked to Alzheimer's Disease

ImportanceMolecular mechanisms linking neuroticism with Alzheimers disease traits are unknown. ObjectiveTo identify molecular subtypes of neuroticism and examine their association with ADRD traits. DesignThree ongoing cohort studies were used; Religious Orders Study (ROS), Rush Memory and Aging Project (MAP) and Minority Aging Research Study (MARS), that began enrollment in 1994, 1997, and 2004, respectively. SettingOlder priests, nuns, and brothers from across the U.S. (ROS), older adults (MAP) and older African-American adults (MARS) from across the greater Chicago metropolitan area. Participants1,028 decedents with multi-omic data from the dorsolateral prefrontal cortex (DLPFC), the anterior cingulate cortex (AC), and the posterior cingulate gyrus (PCG). Exposure(s)Eight layers of omics (DNA methylation and histone acetylation from DLPFC; RNA seq from AC, DLPFC, and PCG, single-nucleus RNA, TMT proteomics and metabolomics from DLPFC) and Neuroticism using the 12-item version from the NEO Five-Factor Inventory. Main outcome(s) and measure(s)Person-specific multi-omic molecular pseudotime representing molecular progression from low to high phenotypic expression of neuroticism, and three multi-omic brain molecular subtypes of neuroticism which represent distinct omic pathways from no/low neuroticism to high neuroticism that differ by their omic constituents. Participants are exclusively assigned to the subtype which aligns mostly with their multi-omic profile. ResultsThe top drivers of subtype differentiation were transcriptomic alterations across three brain regions (DLPFC, AC, PCG) which extensively and differentially characterized the subtypes. The subtypes were also differentially associated with AD pathology, temporal lobe atrophy, and AD dementia, with subtype N1 showing the strongest associations. Conclusions and RelevanceNeuroticism may be driven by three distinct molecular subtypes, with subtype N1 driving ADRD-related associations, N2 showing some ADRD associations, and N3 being completely independent of these outcomes. Our data provide novel insights into the biology of individual differences in predispositions of neuroticism and its associations with ADRD traits. Key pointsO_ST_ABSQuestionC_ST_ABSWhat are the brain multi-omics molecular signatures linking neuroticism with Alzheimers diseases and related dementias (AD/ADRDs)? FindingsWe identified three distinct brain multi-omic molecular subtypes reflecting different molecular pathways underlying neuroticism. Top omic features of the subtypes were extensively and differentially characterized by transcriptomic alterations across three brain regions - dorsolateral prefrontal cortex, anterior cingulate cortex, and posterior cingulate gyrus. Subtype N1 was strongly associated with AD pathology, AD dementia, and temporal lobe atrophy. MeaningThe association we typically observe between phenotypic neuroticism and ADRD clinical traits might be largely driven by a molecular pathway underlying this trait.

neuroscience↗

bioRxiv2024

Spatial Expression of Long Non-Coding RNAs in Human Brains of Alzheimer's Disease

BackgroundLong non-coding RNAs (lncRNAs) are critical regulators of physiological and pathological processes, with their dysregulation increasingly implicated in aging and Alzheimers disease (AD). To investigate the spatial and cellular distribution of lncRNAs in the aging brain, we leveraged published spatial transcriptomics (ST), single-nucleus RNA sequencing (snRNA-seq), and bulk RNA-seq datasets from the dorsolateral prefrontal cortex (DLPFC) of ROSMAP participants with and without pathological AD. ResultsLncRNAs exhibited greater subregion-specific expression than mRNAs, with enrichment in antisense and lincRNA biotypes. Subregion-enriched lncRNAs were generally not cell-type specific, and vice versa. Differential expression analysis of ST data identified AD-associated lncRNAs with distinct spatial patterns and moderate overlap with differentially expressed (DE) lncRNAs from bulk RNA-seq. Gene set enrichment revealed their involvement in chromatin remodeling, epigenetic regulation, and RNA metabolism. We also identified AD DE lncRNAs across major brain cell types using snRNA-seq but overlap with ST DE lncRNAs was limited. Among previously reported lncRNAs, OIP5-AS1 was consistently upregulated in AD in all cortical subregions. Antisense oligonucleotide (ASO) knockdown of OIP5-AS1 in iPSC-derived microglia led to upregulation of pro-inflammatory genes and downregulation of DNA replication and repair pathways. Immunoassays confirmed increased secretion of pro-inflammatory cytokines. The knockdown expression pattern was enriched for microglia-specific AD DE genes and microglia states. ConclusionsThis study provides a spatial and cellular map of lncRNAs in the aging human cortex and identifies subregion-and cell-type-enriched DE lncRNAs in AD. Our findings implicate OIP5-AS1 in microglial activation, suggesting its potential contribution to AD pathogenesis.

neuroscience↗

bioRxiv2024

Uncovering Plaque-Glia Niches in Human Alzheimer's Disease Brains Using Spatial Transcriptomics

Amyloid-beta (A{beta}) plaques and surrounding glial activation are prominent histopathological hallmarks of Alzheimers Disease (AD). However, it is unclear how A{beta} plaques interact with surrounding glial cells in the human brain. Here, we applied spatial transcriptomics (ST) and immunohistochemistry (IHC) for A{beta}, GFAP, and IBA1 to acquire data from 258,987 ST spots within 78 postmortem brain sections of 21 individuals. By coupling ST and adjacent-section IHC, we showed that low A{beta} spots exhibit transcriptomic profiles indicative of greater neuronal loss than high A{beta} spots, and high-glia spots present transcriptomic changes indicative of more significant inflammation and neurodegeneration. Furthermore, we observed that this ST glial response bears signatures of reported mouse gene modules of plaque-induced genes (PIG), oligodendrocyte (OLIG) response, disease-associated microglia (DAM), and disease-associated astrocytes (DAA), as well as different microglia (MG) states identified in human AD brains, indicating that multiple glial cell states arise around plaques and contribute to local immune response. We then validated the observed effects of A{beta} on cell apoptosis and plaque-surrounding glia on inflammation and synaptic loss using IHC. In addition, transcriptomic changes of iPSC-derived microglia-like cells upon short-interval A{beta} treatment mimic the ST glial response and mirror the reported activated MG states. Our results demonstrate an exacerbation of synaptic and neuronal loss in low-A{beta} or high-glia areas, indicating that microglia response to A{beta}-oligomers likely initiates glial activation in plaque-glia niches. Our study lays the groundwork for future pathology genomics studies, opening the door for investigating pathological heterogeneity and causal effects in neurodegenerative diseases.

genomics↗

bioRxiv2024

LRRK2 G2019S variant is associated with transcriptional changes in Parkinson's disease human myeloid cells under proinflammatory environment

The G2019S mutation in the leucine-rich repeat kinase 2 (LRRK2) gene is a major risk factor for the development of Parkinsons disease (PD). LRRK2, although ubiquitously expressed, is highly abundant in cells of the innate immune system. Given the importance of central and peripheral immune cells in the development of PD, we sought to investigate the consequences of the G2019S mutation on microglial and monocyte transcriptome and function. We have generated large-scale transcriptomic profiles of isogenic human induced microglial cells (iMGLs) and patient derived monocytes carrying the G2019S mutation under baseline culture conditions and following exposure to the proinflammatory factors IFN{gamma} and LPS. We demonstrate that the G2019S mutation exerts a profound impact on the transcriptomic profile of these myeloid cells, and describe corresponding functional differences in iMGLs. The G2019S mutation led to an upregulation in lipid metabolism and phagolysosomal pathway genes in untreated and LPS/IFN{gamma} stimulated iMGLs, which was accompanied by an increased phagocytic capacity of myelin debris. We also identified dysregulation of cell cycle genes, with a downregulation of the E2F4 regulon. Transcriptomic characterization of human-derived monocytes carrying the G2019S mutation confirmed alteration in lipid metabolism associated genes. Altogether, these findings reveal the influence of G2019S on the dysregulation of the myeloid cell transcriptome under proinflammatory conditions.

genetics↗

bioRxiv2024

Bridging the Gap: Multi-Omics Profiling of Brain Tissue in Alzheimer's Disease and Older Controls in Multi-Ethnic Populations

INTRODUCTIONMulti-omics studies in Alzheimers disease (AD) revealed many potential disease pathways and therapeutic targets. Despite their promise of precision medicine, these studies lacked African Americans (AA) and Latin Americans (LA), who are disproportionately affected by AD. METHODSTo bridge this gap, Accelerating Medicines Partnership in AD (AMP-AD) expanded brain multi-omics profiling to multi-ethnic donors. RESULTSWe generated multi-omics data and curated and harmonized phenotypic data from AA (n=306), LA (n=326), or AA and LA (n=4) brain donors plus Non-Hispanic White (n=252) and other (n=20) ethnic groups, to establish a foundational dataset enriched for AA and LA participants. This study describes the data available to the research community, including transcriptome from three brain regions, whole genome sequence, and proteome measures. DISCUSSIONInclusion of traditionally underrepresented groups in multi-omics studies is essential to discover the full spectrum of precision medicine targets that will be pertinent to all populations affected with AD.

neuroscience↗